Evidence map›Paper›PMID 21256603›Full record

ReviewTrends in pharmacological sciences2011

Treatment of nicotine addiction: present therapeutic options and pipeline developments.

Riccardo Polosa, Neal L Benowitz

Registry-linked trialAbstract readReview
In one paragraph

Review in Trends in pharmacological sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04231838 (A Randomised Controlled International Multicentre Study Evaluating Changes in Metabolic Syndrome in Smokers With Type 2 Diabetes Mellitus After Switching From Tobacco Cigarettes to Combustion-Free Nicotine Delivery Systems), which is not on this map. Cited by 74 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 2 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04231838 naunknown statusnot on this mapstarted 2021, after this paper: background citation

A Randomised Controlled International Multicentre Study Evaluating Changes in Metabolic Syndrome in Smokers With Type 2 Diabetes Mellitus After Switching From Tobacco Cigarettes to Combustion-Free Nicotine Delivery Systems: DIASMOKE Study

TypeinterventionalSponsorEclat Srl.Ran2021 to 2026Enrolled576ConditionsCardiovascular Risk Factor, Diabetes Mellitus, Type 2ArmsTOBACCO CIGARETTES, COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)
3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 2 syntheses or guidelines pooled it, 140 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. The Importance of Conditioned Stimuli in Cigarette and E-Cigarette Craving Reduction by E-Cigarettes.International journal of environmental research and public health · 2017
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Riccardo PolosaCentro per la Prevenzione e Cura del Tabagismo (CPCT), Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Università di Catania, Catania, Italy. polosa@unict.it
Neal L Benowitz
Azienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele · ITUniversity of California, San Francisco · US

Funding

PHARMACOKINETICS &PHARMACODYNAMICS OF NICOTINER01DA002277 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BENOWITZ, NEAL L · 1985 to 2012
$6.3M
PHARMACOKINETICS AND PHARMACODYNAMICS OF NICOTINER37DA002277 · NIDA · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI BENOWITZ, NEAL L · 1993 to 2002
$1.6M
NIDA NIH HHS R01 DA002277NIDA NIH HHS R37 DA002277
6 · The paper itself

Abstract

Tobacco use is a global pandemic that poses a substantial and costly health burden. There are some treatment options are available, but currently marketed smoking-cessation drugs lack high levels of efficacy, particularly in real-life settings. Consequently, there is a compelling need for more effective pharmacotherapies to aid smokers in maintaining long-term abstinence. Advances in the understanding of the mechanisms involved in nicotine dependence have recently been translated into new medications and vaccines that interfere with nicotine signaling, many of which are currently at an advanced stage of development. In the present article we review current and emerging pharmacotherapies for tobacco dependence, focusing on the mechanistic rationale for their potential anti-addiction efficacy, major findings in preclinical and clinical studies, and future research directions.

Indexed as

Smoking PreventionDrug DesignHumansNicotineSmokingSmoking CessationTobacco Use DisorderVaccinesNicotineVaccines

Identifiers

PMID21256603
PMCPMC5564372
OpenAlexW2057469494

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.